Effective Platform for the Production of Recombinant Outer Membrane Vesicles in Gram-Negative Bacteria
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Bacterial outer membrane vesicles (OMVs) typically contain multiple immunogenic molecules that include antigenic proteins, making them good candidates for vaccine development. In animal models, vaccination with OMVs has been shown to confer protective immune responses against many bacterial diseases. It is possible to genetically introduce heterologous protein antigens to the bacterial host that can then be produced and relocated to reside within the OMVs by means of the host secretion mechanisms. Accordingly, in this study we sought to develop a novel platform for recombinant OMV (rOMV) production in the widely used bacterial expression host species, Escherichia coli. Three different lipoprotein signal peptides including their Lol signals and tether sequences—from Neisseria meningitidis fHbp, Leptospira interrogans LipL32, and Campylobactor jejuni JlpA—were combined upstream to the GFPmut2 model protein, resulting in three recombinant plasmids. Pilot expression studies showed that the fusion between fHbp and GFPmut2 was the only promising construct; therefore, we used this construct for large-scale expression. After inducing recombinant protein expression, the nanovesicles were harvested from cell-free culture media by ultrafiltration and ultracentrifugation. Transmission electron microscopy demonstrated that the obtained rOMVs were closed, circular single-membrane particles, 20–200 nm in size. Western blotting confirmed the presence of GFPmut2 in the isolated vesicles. Collectively, although this is a non-optimized, proof-of-concept study, it demonstrates the feasibility of this platform in directing target proteins into the vesicles for OMV-based vaccine development.
Abstract
Bacterial outer membrane vesicles (OMVs) typically contain multiple immunogenic molecules that include antigenic proteins, making them good candidates for vaccine development. In animal models, vaccination with OMVs has been shown to confer protective immune responses against many bacterial diseases. It is possible to genetically introduce heterologous protein antigens to the bacterial host that can then be produced and relocated to reside within the OMVs by means of the host secretion mechanisms. Accordingly, in this study we sought to develop a novel platform for recombinant OMV (rOMV) production in the widely used bacterial expression host species, Escherichia coli. Three different lipoprotein signal peptides including their Lol signals and tether sequences—from Neisseria meningitidis fHbp, Leptospira interrogans LipL32, and Campylobactor jejuni JlpA—were combined upstream to the GFPmut2 model protein, resulting in three recombinant plasmids. Pilot expression studies showed that the fusion between fHbp and GFPmut2 was the only promising construct; therefore, we used this construct for large-scale expression. After inducing recombinant protein expression, the nanovesicles were harvested from cell-free culture media by ultrafiltration and ultracentrifugation. Transmission electron microscopy demonstrated that the obtained rOMVs were closed, circular single-membrane particles, 20–200 nm in size. Western blotting confirmed the presence of GFPmut2 in the isolated vesicles. Collectively, although this is a non-optimized, proof-of-concept study, it demonstrates the feasibility of this platform in directing target proteins into the vesicles for OMV-based vaccine development.
참고문헌 (29)
- Kulkarni HM, "Biogenesis and multifaceted roles of outer membrane vesicles from Gram-negative bacteria", Microbiology, 160, pp.2109~2121 (2014)
- Kulp A, "Biological functions and biogenesis of secreted bacterial outer membrane vesicles", Annu. Rev. Microbiol, 64, pp.163~184 (2010)
- Ellis TN, "Virulence and immunomodulatory roles of bacterial outer membrane vesicles", Microbiol. Mol. Biol. Rev, 74, pp.81~94 (2010)
- Yu Y-j, "Versatile effects of bacterium-released membrane vesicles on mammalian cells and infectious", inflammatory diseases, 2018, pp.39, 514~533
- Kaparakis-Liaskos M, "Immune modulation by bacterial outer membrane vesicles", Nat. Rev. Immunol, 15, pp.375~387 (2015)
- Seib KL, "Neisseria meningitidis factor H-binding protein fHbp : a key virulence factor and vaccine antigen", Expert Rev. Vaccines, 14, pp.841~859 (2015)
- Acevedo R, "Bacterial outer membrane vesicles and vaccine applications", Front. Immunol, 5, pp.121~ (2014)
- van der Pol L, "Outer membrane vesicles as platform vaccine technology", Biotechnol. J, 10, pp.1689~1706 (2015)
- Gnopo YMD, "Designer outer membrane vesicles as immunomodulatory systems – Reprogramming bacteria for vaccine delivery", Adv. Drug Deliv. Rev, 114, pp.132~142 (2017)
- Zavan L, "Helicobacter pylori growth stage determines the size, protein composition, and preferential cargo packaging of outer membrane vesicles", Proteomics, 19, pp.1800209~ (2019)
- Orench-Rivera N, "Environmentally controlled bacterial vesicle-mediated export", Cell. Microbiol, 18, pp.1525~1536 (2016)
- Gerritzen MJH, "High dissolved oxygen tension triggers outer membrane vesicle formation by Neisseria meningitidis", Microb. Cell Fact, 17, pp.157~ (2018)
- Gerritzen MJH, "Sulfate depletion triggers overproduction of phospholipids and the release of outer membrane vesicles by Neisseria meningitidis", Sci. Rep, 9, pp.4716~ (2019)
- Biagini M, "Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined", Proc. Natl. Acad. Sci. USA, 113, pp.2714~2719 (2016)
- Pinne M, "LipL32 is a subsurface lipoprotein of Leptospira interrogans : presentation of new data and reevaluation of previous studies", PLoS One, 8, pp.51025~51025 (2013)
- Jin S, "JlpA, a novel surface-exposed lipoprotein specific to Campylobacter jejuni, mediates adherence to host epithelial cells", Mol. Microbiol, 39, pp.1225~1236 (2001)
- Almagro Armenteros JJ, "SignalP 5.0 improves signal peptide predictions using deep neural networks", Nat. Biotechnol, 37, pp.420~423 (2019)
- Kim OY, "Preparation of outer membrane vesicle from Escherichia coli", Bioprotocol, 3, pp.e995~ (2013)
- Bartolini E, "Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro", J. Extracell. Vesicles, 2, pp.20181~ (2013)
- Gerritzen MJH, "Bioengineering bacterial outer membrane vesicles as vaccine platform", Biotechnol. Adv, 35, pp.565~574 (2017)
- van de Waterbeemd B, "Quantitative proteomics reveals distinct differences in the protein content of outer membrane vesicle vaccines", J. Proteome Res, 12, pp.1898~1908 (2013)
- Rappazzo CG, "Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB", c mice, 2016, pp.34, 1252~1258
- Salverda MLM, "Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles", Vaccine, 34, pp.1025~1033 (2016)
- Clíona A. O'Dwyer, "Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential", Infection and Immunity, 72(11), pp.6511~6518 (2004), American Society for Microbiology[DOI]
- Leitner D, "A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles", Front. Microbiol, 6, pp.823~ (2015)
- Kuipers K, "Salmonella outer membrane vesicles displaying high densities of pneumococcal antigen at the surface offer protection against colonization", Vaccine, 33, pp.2022~2029 (2015)
- Erin R. Green, "Bacterial Secretion Systems: An Overview", Microbiology Spectrum, 4(1) (2016), American Society for Microbiology[DOI]
- Zückert WR, "Secretion of bacterial lipoproteins : through the cytoplasmic membrane, the periplasm and beyond", Biochim. Biophys. Acta, 1843, pp.1509~1516 (2014)
- Anna Konovalova, "Outer membrane lipoprotein biogenesis: Lol is not the end", Philosophical Transactions of the Royal Society B: Biological Sciences, 370(1679), pp.20150030~ (2015), The Royal Society[DOI]